
Psychiatr News August 18, 2006
Volume 41, Number 16, page 28
© 2006 American Psychiatric Association
Comorbidity Study Results Called Into Question
Rich Daly
The growing area of mental illness comorbidity research may often actually
identify pseudocomorbidity, or conditions that don't exist, researchers point
out.
Frequent use in psychiatric comorbidity research of lifetime prevalence
with mixed-age samples can often produce inaccurate results, several
researchers maintain.
Future comorbidity studies that use lifetime prevalence should require
determination of age of onset, even if only retrospectively, according to a
paper published in the June Archives of General Psychiatry titled
"Lifetime Prevalence and Pseudocomorbidity in Psychiatric
Research."
One of the authors, Chris Hayward, M.D., M.P.H., an associate professor in
the Department of Psychiatry and Behavioral Science and director of clinical
services at Stanford University, said the article was a recognition that
comorbidity in psychiatric illness is an important issue that is drawing
increasing amounts of research. However, the increasing use of mixed-age
samples in estimating comorbidity could lead to misleading conclusions about
the extent of comorbidity.
"We have a methodological concern that applies to many current
studies in which comorbidity is estimated," he told Psychiatric
News.
The methodological concern about estimates of comorbidity applies to the
use of lifetime prevalence rates for two disorders in mixed-age samples. The
authors created a simulated example to demonstrate that even in cases of
randomly associated disorders the use of lifetime prevalence with mixed-age
samples creates the appearance of nonrandom comorbidity.
Although Hayward declined to identify specific examples of problem studies
that have been published, the authors reported that the use of lifetime
prevalence to estimate comorbidity is very common, which could put the results
of many such studies in serious question.
`Be Suspicious'
"One of the major contributions of this article by Kraemer and
colleagues is to alert investigators (and readers) to be suspicious about
lifetime prevalence or lifetime history studies," James Anthony, Ph.D.,
professor and chair of the Department of Epidemiology at Michigan State
University, said in an interview with Psychiatric News.
"Apparently, each generation of psychiatric investigators needs to be
reminded that estimation and study of `lifetime prevalence' and `lifetime
history' are fraught with perilous difficulties and are best
avoided."
Although the authors said no perfect solution for avoiding
pseudocomorbidity exists, one possible way to avoid pseudocomorbidity is to
estimate comorbidity in narrower age ranges.
Smaller age intervals are "the best in terms of reducing the bias,
but the smaller the age grouping, the less generalizable the results are,
because they become more and more narrowly applicable only to people in that
age range," Hayward said.
For example, the National Comorbidity Study (NCS) used 10-year age
groupings as part of its design. Although Hayward and the other paper authors
found no evidence that NCS researchers used the more narrow age groupings to
try to address pseudocomorbidity, the NCS approach was viewed as a good way to
avoid pseudocomorbidity problems.
Solution Not Satisfactory
The pseudocomorbidity problem is further reduced with more narrow age
groupings, but studies that limit participation to same-age participants are
"not a very feasible solution because you can apply the estimate of
comorbidity only to people of that age," Hayward said.
Other approaches could include following a group of people of the same age
over time.
The use of age of onset, even in a cross-sectional study, and Kaplan-Meier
survival curves would allow researchers to show the comorbidity at each age
because they would have the age of onset for the two disorders being studied
by age.
The largest obstacle to the revised approach suggested by the paper's
authors, Anthony said, is that it may require a huge boost in the sample-size
requirements for epidemiological research on psychiatric comorbidity.
"Necessarily, unless the goal is to produce a stratum-specific
estimate only for one to five birth cohorts, the net result of the published
recommendation is to move the budget for a national comorbidity survey well
beyond the scope of the currently available [National Institutes of Health]
budget for such research," Anthony said.
Problems can arise over the accuracy of age of onset, particularly for
disorders that have early onset and when older participants are asked about
the past. Hayward maintains that the age-of-onset approach is preferable to no
effort to address the problem.
Good estimates of comorbidity can also be found through longitudinal
studies that follow participants over time and calculate comorbidity at any
given age, with estimates varying by age.
The presence of pseudocomorbidity impacts both researchers and clinicians
if disorders thought to involve shared factors or to be caused by another
disorder were actually unrelated.
Misinterpreting study results to find comorbidity where there is none may
lead to an entire line of research that tries to explain why the disorders are
comorbid, when it's very possible they are not comorbid at all.
Pseudocomorbidity also may lead clinicians to make assumptions about the
risk for developing a second disorder when little or no risk actually
exists.
An abstract of "Lifetime Prevalence and Pseudocomorbidity in
Psychiatric Research" is posted at
<http://archpsyc.ama-assn.org/cgi/content/abstract/63/6/604>.
Get information about faster international access.
a>
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|